DOCSLIB.ORG

Macrolides Mode of Action Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Macrolides Mode of Action Pdf Macrolides mode of action pdf Continue Examples: Erythromycin (general, erythrocin ®, others) Claritromycin (Biaxin ®) Azithromycin (Sikromax ®) Figure 1. Review of macrolid pharmacology. Mechanism of action: Link with 50S ribosomes subunit and inhibit protein synthesis by blocking the polypeptide exit tunnel, which prevents the peptide chain extending the macrolide binding site in the exit tunnel overlaps the linking areas to which the clindamycin and streptograms bind. Therefore, when resistance develops due to ribosomes methylation, which reduces binding, all three antibiotics are similarly affected. Bacteriostatic (usually) macrolids appear to have an anti- inflammatory effect in community-acquired pneumonia and other chronic inflammatory lung diseases, which contributes to a reduction in hospital stays and mortality (Jaffe s Bush, 2001; Amsden, 2005). Resistance: Methylation ribosome 50S (altered target affinity) Altered permeability of the cell wall (reducing pore expression, or pore expression with altered selectivity) Figure 2. A) Places of action of bacterial protein synthesis inhibitors. B) Macrolid antibiotics have a common macrocyclic structure of lactone ring and residues of deoxed sugar. The structures of erythromycin and claritromycin differ only in one position (circled in green). Structures reproduced from Wikipedia Commons. Spectrum of antimicrobials: Common: Staphylococcus, S. Piogens and C. pneumonia; Bacillus anthracis (anthrax), Legionnaire's disease (Legionella) and Hemophilus ducreyi (Shancroid's disease). Chlamydia, Mycoplasma (clinically useful in patients with hypersensitive penicillin). It is generally more effective against gram-positives against gram-positives because macrolids have a cumbersome structure (see above) that does not penetrate through both membranes into gram-negative bacteria. Indications: Erythromycin: Rarely used to treat infections due to increased resistance and more favorable alternatives, including claritromycin and azithromycin Most commonly used (non-labeled) as prokinetics for the treatment of gastroparosis (to stimulate stomach mobility) (Camilleri et al, 2013; Camilleri, 2015). Preoperative bowel preparation (oral administration of erythromycin base). The basic form of erythromycin is relatively poorly digested (20-50%) from the gastrointestinal tract and is given orally together with neomycin or canamicin as a pre-operation drug of the intestine (to cleanse the intestines of bacteria before surgery). An alternative drug for Legionnaire's disease. Claritromycin: Commonly used for respiratory and sinus infections Treatment infections Helicobacter pylori, hemophilin flu, Mycobacterium avium complex (MAC) . (Note: The treatment of choice for H. pylori stomach ulcers is claritromycin th - proton pump inhibitor in patients without penicillin allergy, or resistance to claritromycin). Azithromycin: Respiratory Infections Skin Infections (SSTIs) STIs STIs GC, chancroid) Traveller's diarrhea Mycobacterium avium complex (MAC) Side effects: mild GI upset hypersensitivity cholestatic jaundice (caused by estolatic erythromycin salt) Inuit cytochrome P-450 (medical interactions), but not with azithromycin Tk prolongation and Thorsada de Pointe high concentrations of erythromycin (usually after i.v. (or claritromycin. In vitro studies confirm that they are K heart channel blockers at a high therapeutic level (Stanat et al., 2003). Pharmacokinetics: Erythromycin: orally absorbed as stearat or estolate salt, penetration of CSF poor, bile and fecal secretions. Acid labile and absorption of salt compounds from the gastrointestinal tract is a variable. It is necessary to give 2 hours before or after meals. The unsalted (basic) form is not very well absorbed when taken orally and is used to sterilize the intestines before surgery. Claritromycin: Twice a day of pre-sission; acid is stable with a better absorption of GI than erythromycin. Azithromycin: Once a day of pre-sission; must be given 2 hours before or after meals. The main drug interactions: Erythromycin and its metabolites and claritracin can inhibit CYP3A4 and thus increase the plasma concentration of numerous drugs. The use of other drugs that prolong the interval of ER with erythromycin or claritromycin should be done carefully, as both are known cardiac blockers of channel K (Stanat et al., 2003). References: Amsden GW (2005): Anti-inflammatory effects of macrolids - an underestimated advantage in the treatment of community respiratory infections and chronic inflammatory lung diseases? J Antimicrobial Chemotherapy 55:10-21. Bartlett JG, Auwaerter PG, Pham PA (2010): Johns Hopkins ABX Guide. Diagnosis and treatment of infectious diseases. 2010 2nd edition. Jones and Bartlett Publishers, Sudbury MA. (ISBN: 978-0-7637-8108-8) Camilleri M et al (2013): Clinical Guide: Gastropares Management. Am J Gastroenterol 108:18-37. doi: 10.1038/ajg.2012.373. Camilleri M (2015): Treatment of gastroparesis. In: UpToDate. Basow DS (Ed), Waltham, Massachusetts. 11/4/15 is quoted. Deck DH, Winston LG (2012): Tetracycline, Macrolides, Clindamycin, Chloramphenicol, Streptogramn and Oxazoridion (Chapter 44). In: Basic and Clinical Pharmacology. 12e. Katzung BG, Masters SB, Trevor AJ (editors). McGraw Hill / Lange. Jaffe A, Bush A (2001): Anti-inflammatory action of macrolids in lung disease. Children's pulmonology. 31(6):464-473. Stanat SJ, Carlton CG, Crumb WJ Jr, Agrawal KC, Clarkson CW (2003): Characteristics of inhibitory effects of erythromycin and claritromycin on the herg potassium channel. Mole cell biochemistry 254 (1-2):1-7. rxlist.com (Erythrocin ®) macrolide, erythromycin, claritromycin, azithromycin Articles Content Figures and Table Video Audio data you currently do not have access to this article. Prices for subscription and order To buy short-term access, access, enter into your Oxford academic account above. You don't have an academic account at Oxford yet? Register the chemistry and mode of action of macrolids - 24 hours of access to erythromycin. The macrolide ring is a lacton (cyclical esther) in the upper left. Claitromycin Roxithromycin macrolidees are a class of natural products that consist of a large macrocyclic lactonic ring to which one or more deoxy sugars, usually cladinos and deosasamine, can be attached. Lacton rings are usually 14-, 15-, or 16-membered. Macrolids belong to the class of polyketides of natural products. Some macrolids have antibiotics or antifungal activity and are used as pharmaceuticals. Macrolides are bacteriotic in that they inhibit or inhibit bacterial growth rather than kill bacteria completely. The story of the first discovered macrolide was erythromycin, which was first used in 1952. Erythromycin was widely used as a substitute for penicillin when patients were allergic to penicillin or penicillin-resistant diseases. Later macrolides, including azithromycin and claritromycin, flow from chemically modifying erythromycin; These compounds have been designed to be more easily digested and have fewer side effects (erythromycin has caused gastrointestinal side effects in a large proportion of users). Antibiotics are used to treat infections caused by gram-positive bacteria (e.g. streptococcal pneumonia) and limited gram-negative bacteria (e.g. Bordetell whooping cough, hemophilic influenza), as well as certain respiratory and soft tissue infections. The antimicrobial spectrum of macrolides is slightly wider than that of penicillin, and therefore macrolides are a common substitute for patients with penicillin allergies. Beta-hemolytic streptococcus, pneumococcus, staphylococcus and enterococcus are generally susceptible to macrolides. Unlike penicillin, macrolides have been shown to be effective against Legionella pneumophile, mycoplasma, mycobacteria, some rickettsia and chlamydia. Macrolids should not be used on non-gruminant herbivores such as horses and rabbits. They quickly produce a reaction, causing a fatal digestive disorder. It can be used in horses under the age of one, but it is necessary to ensure that other horses (such as the mother of the foal) do not come into contact with macrolide treatment. Macrolids can be injected in a variety of ways that include pills, capsules, suspensions, injections and locally. The mechanism of action of Antibacterial Macrolids are inhibitors of protein synthesis. The mechanism of action of macrolides is to inhibit the biosynthesis of bacterial protein, and they are believed to do so by preventing peptiyltransferase from adding a growing peptide, to the tRNA to the next amino acid (similar to chloramphenicol), as well as inhibition of ribosomes. Another potential mechanism mechanism premature dissoturcation of peptiyl-tRNA from ribosome. Macrolid antibiotics do this by binding reversibly to site P on the 50S subdivision of bacterial ribosome. This action is considered bacteriotic. Macrolids are actively concentrated in white blood cells and are thus transported to the site of infection. Immunomodulation of diffuse panbronchiolite macrolid antibiotics erythromycin, claritromycin and Roxytromycin proved to be effective long-term treatment of idiopathic, common in Asia lung diseases with diffuse panbronchiolitis (DPB). The successful results of macrolides in WPV stem from symptom control through immunomodulation (adjustment of the immune response), with the added benefit of low doses. With macrolide therapy in WPV, a significant reduction in bronchiolar inflammation and damage is achieved by suppressing not only the proliferation of neutrophils granulocytes,
Load more

Recommended publications
  • UV-Curable Coating Composition
    Europaisches Patentamt European Patent Office (fi) Publication number: 0 001 466 A1 Office europeen des brevets EUROPEAN PATENT APPLICATION 2y Application number: 78200215.8 © int. ci.*: C 09 D 3/49, C 08 F 299/00, C 08 F 2/50 §) Date of filing: 28.09.78 © Priority: 11.10.77 NL 7711121 Applicant: Akzo N.V., Ijssellaan 82, NL-6800 LS Arnhem (NL) (7g) Inventor: Noomen, Arie, Schoonoord 22, NL-2215 Ed @ Date of publication of application: 18.04.79 Voorhout (NL) Bulletin 79/8 Inventor: Wolters, Egbert, Potgieterstraat 21, NL-1053 XP Amsterdam (NL) @ Representative: Sieders, Rene et ai, P.O.Box 314, @ Designated Contracting States: BE DE FR GB NL SE NL-6800 AH Arnhem (NL) @ U.V.-curable coating composition. The invention relates to a coating composition which is curable under the influence of ultraviolet light and which comprises a U.V.-curable binder, a photoinitiator and as accelerator a tetrahydro-1,3-oxazine compound and/or an oxazolidine compound. The U.V.-curable binder is pref- erably an adduct containing at least one isocyanate group of a) an acrylic or methacrylic hydroxy ester having 5 to 20 carbon atoms and b) a polyisocyanate having 4 to 40 carbon atoms and 2 to 4 isocyanate groups. The invention relates to a coating composition which can be cured under the influence of ultraviolet light ;and is based on a U.V.-curable binder, a photoinitiator and a nitrogen-containing accelerator. In known com- positions useismade generally of an aromatic carbonyl compound as photoinitiator, and of an alkanolamine as accelerator.
    [Show full text]
  • Phamarcological Effects Produced by the Modifications in Isoxazole Moeities
    Archana c. et al. / Asian Journal of Phytomedicine and Clinical Research. 4(1), 2016, 29 - 32. Review Article CODEN: AJPCFF ISSN: 2321 – 0915 Asian Journal of Phytomedicine and Clinical Research Journal home page: www.ajpcrjournal.com PHAMARCOLOGICAL EFFECTS PRODUCED BY THE MODIFICATIONS IN ISOXAZOLE MOEITIES C. Archana *1 , E. Akila 2, Priya john 3 1*Department of Pharmaceutical Chemistry, Prime College of Pharmacy, Palakkad, Kerala, India. 2Department of Pharmacognosy, Prime College of Pharmacy, Palakkad, Kerala, India. 3Department of Pharmacology, Prime College of Pharmacy, Palakkad, Kerala, India. ABSTRACT Isoxazole and its derivatives are an important class of heterocyclic compound displaying a broad spectrum of biological activities which have made them privileged structures. In the present work, attempts were made to identify leading isoxazole moieties as candidate drugs against many diseases. For example, isoxazole substituted 9-anilino acridine derivatives was found to have increased antioxidant activities. The molecular docking studies show a good correlation between their biological activities screened and auto dock binding free energy. These derivatives will encourage helping to design future anti cancer agents with higher therapeutic potential. Another example is isoxazole incorporated 2-quinolones to show increased antimicrobial and anti inflammatory activities. More importantly, various isoxazole derivatives greatly increase biological properties of the structure like anti-infective action, anticancer properties, anti-protozoal and mutagenic properties. A modification in their structures has offered a high degree of diversity that has proven useful for the development of new therapeutic agents having improved potency and lesser toxicity. In the present study of concise review, is provided on the activities of isoxazole and its derivatives which involve history, chemistry, different methods of synthesis of isoxazole with biological activities and docking studies.
    [Show full text]
  • We Have Reported That the Antibiotics Chloramphenicol, Lincomycin
    THE BIOGENESIS OF MITOCHONDRIA, V. CYTOPLASMIC INHERITANCE OF ERYTHROMYCIN RESISTANCE IN SACCHAROMYCES CEREVISIAE* BY ANTHONY W. LINNANE, G. W. SAUNDERS, ELLIOT B. GINGOLD, AND H. B. LUKINS BIOCHEMISTRY DEPARTMENT, MONASH UNIVERSITY, CLAYTON, VICTORIA, AUSTRALIA Communicated by David E. Green, December 26, 1967 The recognition and study of respiratory-deficient mutants of yeast has been of fundamental importance in contributing to our knowledge of the genetic control of the formation of mitochondria. From these studies it has been recognized that cytoplasmic genetic determinants as well as chromosomal genes are involved in the biogenesis of yeast mitochondria.1' 2 Following the recog- nition of the occurrence of mitochondrial DNA,3 4 attention has recently been focused on the relationship between mitochondrial DNA and the cytoplasmic determinant.' However, the information on this latter subject is limited and is derived from the study of a single class of mutant of this determinant, the re- spiratory-deficient cytoplasmic petite. This irreversible mutation is pheno- typically characterized by the inability of the cell to form a number of compo- nents of the respiratory system, including cytochromes a, a3, b, and c1.6 A clearer understanding of the role of cytoplasmic determinants in mitochondrial bio- genesis, could result from the characterization of new types of cytoplasmic mutations which do not result in such extensive biochemical changes. This would thus simplify the biochemical analyses as well as providing additional cytoplasmic markers to assist further genetic studies. We have reported that the antibiotics chloramphenicol, lincomycin, and the macrolides erythromycin, carbomycin, spiramycin, and oleandomycin selec- tively inhibit in vitro amino acid incorporation by yeast mitochondria, while not affecting the yeast cytoplasmic ribosomal system.7' 8 Further, these antibiotics do not affect the growth of S.
    [Show full text]
  • Macrocyclic Antibiotics As Separation Agents
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Missouri University of Science and Technology (Missouri S&T): Scholars' Mine Missouri University of Science and Technology Scholars' Mine Chemistry Faculty Research & Creative Works Chemistry 07 Mar 2006 Macrocyclic Antibiotics as Separation Agents Daniel W. Armstrong Missouri University of Science and Technology Follow this and additional works at: https://scholarsmine.mst.edu/chem_facwork Part of the Chemistry Commons Recommended Citation D. W. Armstrong, "Macrocyclic Antibiotics as Separation Agents," U.S. Patents, Mar 2006. This Patent is brought to you for free and open access by Scholars' Mine. It has been accepted for inclusion in Chemistry Faculty Research & Creative Works by an authorized administrator of Scholars' Mine. This work is protected by U. S. Copyright Law. Unauthorized use including reproduction for redistribution requires the permission of the copyright holder. For more information, please contact [email protected]. USOO70O8533B2 (12) United States Patent (10) Patent No.: US 7,008,533 B2 Armstrong (45) Date of Patent: Mar. 7, 2006 (54) MACROCYCLIC ANTIBIOTICSAS (52) U.S. Cl. ............................... 210/1982; 21.0/502.1; SEPARATION AGENTS 210/635; 210/656 (58) Field of Classification Search ................ 210/635, (75) Inventor: Daniel Armstrong, Rolla, MO (US) 210/656, 198.2, 502.1; 502/.401, 403, 404; 435/174, 176, 178,180 (73) Assignee: Curators of the University of See application file for complete Search history. Missouri, Columbia, MO (US) (*) Notice: Subject to any disclaimer,- 0 the term of this (56) References Cited patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C.
    [Show full text]
  • Isoxazoles: Molecules with Potential Medicinal Properties
    IJPCBS 2013, 3(2), 294-304 Jayaroopa et al. ISSN: 2249-9504 INTERNATIONAL JOURNAL OF PHARMACEUTICAL, CHEMICAL AND BIOLOGICAL SCIENCES Available online at www.ijpcbs.com Research Article ISOXAZOLES: MOLECULES WITH POTENTIAL MEDICINAL PROPERTIES K. Ajay Kumar and P. Jayaroopa* Post Graduate Department of Chemistry, Yuvaraja’s College, University of Mysore, Mysore-570 005, India. ABSTRACT Isoxazole is a five membered heterocyclic compound having various pharmacological actions. The great interest associated with isoxazoles and their derivatives is based on their versatility as synthetic building blocks, their latent functionalities as enaminones, 1,3-dicarbonyl compounds, γ-amino alcohols, and β-hydroxy nitriles have been widely exploited for the synthesis of other heterocycles and complex molecules. This review paper comprises of up to date information on isoxazole analogs. More emphasis was given to critical discussion on the synthetic strategy of isoxazole derivative, their utility as building blocks in their transformation to more biologically potent molecules. Results of isoxazole derivatives and their substitutions effect on diverse biological activities also presented. Keywords: Isoxazoles, antioxidant, antimicrobial, analgesic, anti-platelet, anti-HIV. INTRODUCTION sulfisoxazole, oxacillin, cycloserine and acivicin Nitrogen containing heterocycles with an have been in commercial use for many years. oxygen atom are considered as an important Cycloserine is the best known antibiotic drug class of compounds in medicinal chemistry that possess antitubercular, antibacterial because of their diversified biological activities and in treatment of leprosy. Acivicin is applications. The exploitation of a simple an antitumour, antileishmania drug, while molecule with different functionalities for the isoxaflutole is used as herbicidal drug. synthesis of heterocycles is a worthwhile Isoxazoles have illustrious history; their contribution in the chemistry of heterocycles.
    [Show full text]
  • Matrix Scientific PO BOX 25067 COLUMBIA, SC 29224-5067 Telephone: 803-788-9494 Fax: 803-788-9419 SAFETY DATA SHEET Transportation Emergency: 3E Co
    Matrix Scientific PO BOX 25067 COLUMBIA, SC 29224-5067 Telephone: 803-788-9494 Fax: 803-788-9419 SAFETY DATA SHEET Transportation Emergency: 3E Co. (5025) 800-451-8346 1. Product Identification Name Oxazolidine-2,5-dione Catalog Number 094908 CAS Registry Number [2185-00-4] Company Matrix Scientific Physical Address 131 Pontiac Business Center Drive Elgin, SC 29045 USA Telephone/Fax (803)788-9494/(803)788-9419 2. Hazard Identification Hazardous Ingredients Oxazolidine-2,5-dione GHS label elements, including precautionary statements Pictogram Signal word WARNING Hazard statement(s) H317 May cause an allergic skin reaction H319 Causes serious eye irritation Precautionary statement(s) P280 Wear protective gloves/protective clothing/eye protection/face protection. P305+351+338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. 3. Composition, Information or Ingredients Name Oxazolidine-2,5-dione 4. First Aid Measures Eye Contact: Check for and remove any contact lenses. Immediately flush 1 Last Updated 2/11/2017 eyes with clean, running water for at least 15 minutes while keeping eyes open. Cool water may be used. Seek medical attention. Skin Contact: After contact with skin, wash with generous quantities of running water. Gently and thoroughly wash affected area with running water and non- abrasive soap. Cool water may be used. Cover the affected area with emollient. Seek medical attention. Wash any contaminated clothing prior to reusing. Inhalation: Remove the victim from the source of exposure to fresh, uncontaminated air. If victim's breathing is difficult, administer oxygen. Seek medical attention.
    [Show full text]
  • A New Class of Anticancer Agents
    Chem Biol Drug Des 2014; 83: 126–131 Research Letter Mefloquine–Oxazolidine Derivatives: A New Class of Anticancer Agents Felipe A. R. Rodrigues1, Igor da S. Bomfim1, applications in other fields, such as against Gram-positive Bruno C. Cavalcanti1, Claudia Pessoa1, Raoni and Gram-negative bacteria (1), in particular against Myco- S. B. Goncalves2, James L. Wardell2,3, Solange bacterium tuberculosis (2,3) and Mycobacterium avium M. S. V. Wardell4 and Marcus V. N. de Souza2,* complex (MAC) (4,5) and also against schistosomiasis (6), neurodegenerative, and (neuro-) inflammatory diseases (7). 1Laboratorio de Oncologia Experimental, Universidade A clear indication of the promise of this drug in fields other Federal do Ceara, Fortaleza, CE 3157, Brazil than malaria is the number of recent patent applications 2FioCruz-Fundacßao~ Oswaldo Cruz, Instituto de Tecnologia (5,7,8). More recently, much attention has been paid to the em Farmacos-Far-Manguinhos, Rua Sizenando Nabuco, potential perspectives of MQ as an anticancer agent. As 100, Manguinhos, 21041-250, Rio de Janeiro, RJ 35513, estimated by the National Institutes of Health (NIH), the over- Brazil all costs of cancer in 2007 were $226.8 billion.a Cancer is a 3Department of Chemistry, University of Aberdeen, Old leading cause of deaths worldwide and accounted for 7.6 Aberdeem, Aberdeem, AB 24 3UE, UK b 4CHEMSOL, 1 Harcourt Road, Aberdeen, AB15 5NY, UK million deaths (13% of all deaths) in 2008. Louie and *Corresponding author: Marcus V. N. de Souza, coworkers (9) found MQ to be the most potent anticancer marcos_souza@far.fiocruz.br drug when compared to chloroquine and the fluoroquino- lone drugs cipro and levofloxacin.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,977,285 Ernst MOOS Et Al
    USOO5977285A United States Patent (19) 11 Patent Number: 5,977,285 Ernst MOOS et al. (45) Date of Patent: Nov. 2, 1999 54 SPRAYABLE COATING COMPOSITIONS 992721 5/1965 United Kingdom. WO 92/13907 8/1992 WIPO ............................ CO8G 18/10 COMPRISING OXAZOLIDINES, ISOCYANATES AND HYDROXYL OR AMINE WO 93/17060 9/1993 WIPO ............................ CO8G 63/02 FUNCTIONAL RESNS WO 94/27746 12/1994 WIPO .............................. BO5D 7/24 WO95/14528 6/1995 WIPO .............................. B01J 13/OO (75) Inventors: Jan Wilhelm Ernst Moos, Bloomfield WO 96/083O8 3/1996 WIPO .............................. B01J 13/OO Hills; Heide Anne Lochbiler, East OTHER PUBLICATIONS Pointe; Jason Donald Weaver, New Angus Chemical Company Technical Bulletin TB 91 Zol Baltimore; Latoska Nikita Price, dine(R) RD-20, 1–8 (1994). Southfield; Frances Lamb, Northville; International Search Report, dated Nov. 27, 1998 (PCT/ Donald Lynn Rutledge, Jr., Clawson, EP98/04942). all of Mich.; Ann Alfred Johanna International Search Report, dated Dec. 4, 1998 (PCT/EP98/ Lemaire, Leiderdorp, Netherlands; 04943). Antonius Hendrikus Gerardus Van International Search Report, dated Dec. 11, 1998 (PCT/ Engelen, Alphen A/D Rijn, Netherlands; EP98/04944). Catharine Marie den Breejen, Rohm and Haas Comppany Acryloid(R) Resins, Maintenance Dordrecht, Netherlands and Marine Coatings, Experimental Reactive Modifier QM-1007M, Reactive Diluent for Increasing Paint Solids Assignee: Akzo Nobel N.V., Netherlands and Improving Film Build of Acrylic-Urethane Coating, 1990, pp. 1–20. Appl. No.: 08/906,645 Donald C. Schall, High Solids Isocyanate-Oxazolidine Filed: Aug. 7, 1997 Coatings, Presented at the Water-Borne & High-Solids coatings Symposium, Feb. 13-15, 1985, New Orleans, Loui Int.
    [Show full text]
  • Ep 2079311 B1
    (19) TZZ Z¥___T (11) EP 2 079 311 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A01N 47/00 (2006.01) 08.03.2017 Bulletin 2017/10 (86) International application number: (21) Application number: 07844213.4 PCT/US2007/081195 (22) Date of filing: 12.10.2007 (87) International publication number: WO 2008/051733 (02.05.2008 Gazette 2008/18) (54) BIGUANIDE COMPOSITION WITH LOW TERMINAL AMINE BIGUANID-ZUSAMMENSETZUNG MIT GERINGEM ENDGRUPPEN-AMIN-ANTEIL COMPOSITION DE BIGUANIDE AVEC AMINE TERMINALE BASSE (84) Designated Contracting States: (72) Inventor: HEILER, David Joseph AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Avon, NY 14414 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (74) Representative: Riegler, Norbert Hermann et al Lonza Ltd. (30) Priority: 23.10.2006 US 853579 P Patent Department 20.03.2007 US 895770 P Münchensteinerstrasse 38 4052 Basel (CH) (43) Date of publication of application: 22.07.2009 Bulletin 2009/30 (56) References cited: WO-A-00/35861 WO-A-98/20738 (73) Proprietor: Arch Chemicals, Inc. US-A- 4 954 636 US-A- 5 965 088 Norwalk, CT 06856-5204 (US) US-A1- 2003 032 768 US-B1- 6 423 748 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Chemicals Subject to TSCA Section 12(B) Export Notification Requirements (January 16, 2020)
    Chemicals Subject to TSCA Section 12(b) Export Notification Requirements (January 16, 2020) All of the chemical substances appearing on this list are subject to the Toxic Substances Control Act (TSCA) section 12(b) export notification requirements delineated at 40 CFR part 707, subpart D. The chemicals in the following tables are listed under three (3) sections: Substances to be reported by Notification Name; Substances to be reported by Mixture and Notification Name; and Category Tables. TSCA Regulatory Actions Triggering Section 12(b) Export Notification TSCA section 12(b) requires any person who exports or intends to export a chemical substance or mixture to notify the Environmental Protection Agency (EPA) of such exportation if any of the following actions have been taken under TSCA with respect to that chemical substance or mixture: (1) data are required under section 4 or 5(b), (2) an order has been issued under section 5, (3) a rule has been proposed or promulgated under section 5 or 6, or (4) an action is pending, or relief has been granted under section 5 or 7. Other Section 12(b) Export Notification Considerations The following additional provisions are included in the Agency's regulations implementing section 12(b) of TSCA (i.e. 40 CFR part 707, subpart D): (a) No notice of export will be required for articles, except PCB articles, unless the Agency so requires in the context of individual section 5, 6, or 7 actions. (b) Any person who exports or intends to export polychlorinated biphenyls (PCBs) or PCB articles, for any purpose other than disposal, shall notify EPA of such intent or exportation under section 12(b).
    [Show full text]
  • Tetrahedron, 65, 6746-6753
    Tetrahedron 65 (2009) 6746–6753 Contents lists available at ScienceDirect Tetrahedron journal homepage: www.elsevier.com/locate/tet Development of a general, enantioselective organocatalytic Mukaiyama–Michael reaction with a,b-unsaturated aldehydes Christopher J. Borths a,b, Diane E. Carrera a,b, David W.C. MacMillan a,b,* a Merck Center for Catalysis, Princeton University, Princeton, NJ 08544, United States b The Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125, United States article info abstract Article history: LUMO-lowering organocatalysis has been extended to promote the conjugate addition of S-alkyl and Received 16 June 2009 1-pyrrolyl silylketene acetals to a,b-unsaturated aldehydes, yielding both, syn and anti Mukaiyama– Received in revised form 17 June 2009 Michael products with high levels of enantioselectivity. This strategy allows for the generation of Accepted 18 June 2009 chemically useful 1,5-dicarbonyl systems and again highlights the utility of organocatalysis. Available online 23 June 2009 Ó 2009 Published by Elsevier Ltd. Keywords: Mukaiyama–Michael Enantioselective organocatalysis 1. Introduction Lewis Acid Catalysis: 1,2-Addition, Mukaiyama-Aldol Since its discovery in 1974, the Mukaiyama–Michael reaction OSiR3 O OH Lewis Acid has become a powerful chemical tool for carbon–carbon fragment (1) RX R O Catalysis RX R couplings with the accompanying formation of vicinal carbon-sp3 Me Me stereochemistry.1 During this time, the inherent selectivity of latent enolates (such as silylketene acetals and enol silanes) to undergo conjugate addition to unsaturated ketones, imides and esters in the Organocatalysis: 1,4-Addition, Mukaiyama-Michael presence of Lewis acids has rendered the Mukaiyama–Michael a mainstay transformation in chemical synthesis.2,3 It is surprising OSiR3 O R Iminium (2) to consider, therefore, that a,b-unsaturated aldehydes have been RX R O RX O Catalysis largely bypassed as electrophilic coupling partners in this venera- Me Me ble 1,4-addition.
    [Show full text]